There is a growing relation between Theme 1 & 2 combined and Theme 3, where advanced radiation therapy treatments are associated with improved outcomes or serve as platforms to develop biological models for therapy prediction and personalization. El Naqa’s group uses computer simulations and experimental animal models along with advanced bioinformatics tools to link physical radiation treatment parameters (dosimetry, online & post-treatment imaging) to endpoints of clinical and biological nature (biomarkers). Devic’s innovative research on FDG-PET/CT image data extraction for radiotherapy treatment planning pave the way to techniques to complement computed tomography-based gross tumor volume definition (GTV) with functional positron emission tomography-based volumes and to represent individual biological targets in need of more targeted radiation doses. Nadeau and her group work on the development of sensitized noble metal and semiconductor nanoparticles for photodynamic and radiation therapy as well as on the development of new synthesis and conjugation procedures to optimize singlet oxygen production from nanoparticles, as well as methods of quantification of nanomaterial toxicity to cancer cells and healthy cells. Active collaborations are present between her group and Seuntjens’ and El-Naqa’s groups to investigate application of these novel nanoparticles to radiation effect enhancement.

The activities of the researchers in the MPRTN CREATE program have led to a growing network of active collaborations between the PIs and the medical devices industry such as Modus Medical , Varian , Elekta , Standard Imaging , Sun Nuclear , Ashland , Dumaine Precision , etc. Other partners in the program are from the regulatory agency the Canadian Nuclear Safety Commission , and the research organization National Research Council, Canada Ionizing Radiation Standards group as well as Harvard Medical School (Francis H Burr Proton Center).